Changes in Hong Kong stocks | Haixi New Pharmaceutical (02637) rose more than 3% and recently submitted a DME phase IIa clinical trial application for HX9428

The Zhitong Finance App learned that Haixi New Pharmaceutical (02637) rose by more than 3%. As of press release, it had risen 2.89% to HK$195.5, with a turnover of HK$6.182,600.

According to the news, Haixi New Pharmaceutical announced that HX9428, the drug candidate molecule HXP056, an innovative drug project independently developed by the company, has officially submitted a Phase IIa new drug clinical trial application (IND) for the new indication diabetic macular edema (DME) to the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) on August 31, 2026. DME is the second indication promoted by HX9428, marking another milestone in the development of this innovative oral intraocular drug. The company said it will continue to make every effort to advance many clinical studies of HX9428 in China and the US.

The company stated that HX9428 has been granted Fast Track Designation (“FTD”) by the U.S. Food and Drug Administration (“FDA”) and is simultaneously carrying out the first indicative neovascularization age-related macular degeneration (neovascular age-related macular degeneration) in China and the US “NaMD”, also known as wet age-related macular degeneration, wAMd) is a phase II clinical study.